AVP Receptor V3 Inhibitors
AVP receptor V3 inhibitors belong to a specialized class of chemical compounds designed to target the AVP (Arginine Vasopressin) receptor V3, also known as the vasopressin 1B receptor (V1B receptor). These receptors are part of the vasopressin receptor family, which includes V1A, V1B (V3), and V2 receptor subtypes. AVP is a peptide hormone that plays essential roles in regulating various physiological processes, including water reabsorption in the kidneys, vasoconstriction, and the stress response. The V3 receptor subtype, which is predominantly found in the anterior pituitary gland and certain brain regions, is primarily associated with the modulation of the hypothalamic-pituitary-adrenal (HPA) axis and the release of adrenocorticotropic hormone (ACTH) in response to stress.
Inhibitors targeting AVP receptor V3 are designed to interact with this receptor and modulate its activity, influencing the downstream signaling pathways and physiological responses associated with AVP-V3 receptor activation. These inhibitors may operate through various mechanisms, such as binding to specific receptor sites or altering receptor conformation. By inhibiting AVP receptor V3, these compounds can affect the stress response, hormone secretion, and other processes regulated by the HPA axis. Research on AVP receptor V3 inhibitors is primarily focused on unraveling the molecular mechanisms underlying the function of this receptor subtype and its role in stress-related physiology and behavior, contributing to our understanding of neuroendocrinology and the intricacies of the stress response system.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Lithium | 7439-93-2 | sc-252954 | 50 g | $214.00 | ||
Lithium is known to modulate G-protein-coupled receptor signaling and could indirectly downregulate AVPR3 expression. | ||||||
Dexamethasone | 50-02-2 | sc-29059 sc-29059B sc-29059A | 100 mg 1 g 5 g | $91.00 $139.00 $374.00 | 36 | |
A glucocorticoid that can affect gene transcription and may reduce AVPR3 expression through negative feedback mechanisms. | ||||||
Tamoxifen | 10540-29-1 | sc-208414 | 2.5 g | $272.00 | 18 | |
An estrogen receptor modulator that might alter the hormonal regulation of AVPR3 expression. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
An activator of protein kinase C which could modify signaling pathways and potentially downregulate AVPR3. | ||||||
Cyclosporin A | 59865-13-3 | sc-3503 sc-3503-CW sc-3503A sc-3503B sc-3503C sc-3503D | 100 mg 100 mg 500 mg 10 g 25 g 100 g | $63.00 $92.00 $250.00 $485.00 $1035.00 $2141.00 | 69 | |
An immunosuppressant that affects calcineurin signaling; this might indirectly lead to reduced AVPR3 expression. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
This mTOR inhibitor affects multiple signaling pathways and could indirectly decrease AVPR3 expression. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
A p38 MAPK inhibitor that might modulate stress-related pathways and influence AVPR3 expression. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
A PI3K inhibitor that can affect numerous signaling pathways, potentially reducing AVPR3 expression. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
An ERK pathway inhibitor which could indirectly affect the regulation of AVPR3 gene expression. | ||||||
Spironolactone | 52-01-7 | sc-204294 | 50 mg | $109.00 | 3 | |
As an aldosterone antagonist, it could interfere with hormone balance and influence AVPR3 expression. | ||||||